Podcasts about american society

As colorectal cancer rates rise among younger adults, surgeons are increasingly caring for patients with rectal cancer who are pregnant or hoping to preserve future fertility. With more individuals delaying childbearing, balancing effective cancer treatment with fertility preservation and maternal–fetal safety has become an important clinical challenge. This timely topic was recently highlighted by Dr. Sharon Suwanabol during a presentation at the American Society of Colon and Rectal Surgeons annual meeting 2026. In this episode, we explore the intersection of rectal cancer, fertility, and pregnancy through a multidisciplinary, case-based discussion. We review how surgery, chemotherapy, and pelvic radiation can affect fertility and sexual function in both men and women, and why early counseling and referral to reproductive endocrinology specialists are essential. The discussion also emphasizes that evaluation and treatment during pregnancy can often be performed safely, with care individualized based on tumor stage, gestational age, and the patient's goals and values. Hosts and discussants ·      Dr. Betelhem Yohannes, General surgery resident at the University of Washington ·      Dr. Griffen Allen, General surgery resident at the University of Washington  ·      Dr. Raga Siddharthan, Assistant Professor of Surgery in the Section of Colorectal Surgery at the University of Washington  ·      Dr. Stacey Cohen, Professor in the Division of Hematology and Oncology at the University of Washington and a gastrointestinal medical oncologist at Fred Hutch Cancer Center, specializing in colorectal and other GI cancers. Learning objectives ·      Describe the impact of rectal cancer surgery on fertility, sexual function, and future childbearing potential. ·      Review the effects of chemotherapy and pelvic radiation on reproductive health and fertility preservation. ·      Discuss available fertility preservation strategies and the importance of early pre-treatment counseling and referral. ·      Recognize the diagnostic challenges of rectal cancer during pregnancy, including overlapping gastrointestinal symptoms. ·      Review appropriate staging and workup considerations for suspected rectal cancer in pregnant patients. ·      Discuss multidisciplinary management strategies for rectal cancer during pregnancy, including individualized treatment sequencing. ·      Examine ethical and patient-centered considerations when balancing maternal cancer treatment and fetal outcomes. References  Siegel RL, Wagle NS, Star J, Kratzer TB, Smith RA, Jemal A. Colorectal cancer statistics, 2026. CA Cancer J Clin. 2026;76(2):e70067. doi:10.3322/caac.70067 [https://pubmed.ncbi.nlm.nih.gov/38240409/] Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11. Obstet Gynecol. 2022;140(2):348-366. doi:10.1097/AOG.0000000000004873 [https://pubmed.ncbi.nlm.nih.gov/35640237/] Stal J, YI SY, Cohen-Cutler S, et al. Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates. Oncologist. 2022;27(7):579-586. doi:10.1093/oncolo/oyac052 [https://pubmed.ncbi.nlm.nih.gov/35708892/] Druvefors E, Myrelid P, Andersson RE, Landerholm K. Female and Male Fertility after Colectomy and Reconstructive Surgery in Inflammatory Bowel Disease: A National Cohort Study from Sweden. J Crohns Colitis. 2023;17(10):1631-1638. doi:10.1093/ecco-jcc/jjad079 [https://pubmed.ncbi.nlm.nih.gov/37341355/] Ito M, Tsukada Y, Watanabe J, et al. Long-term survival and functional outcomes of laparoscopic surgery for clinical stage I ultra-low rectal cancers located within 5 cm of the anal verge: A prospective phase II trial (Ultimate trial). Ann Surg. Published online April 1, 2024. doi:10.1097/SLA.0000000000006290 [https://pubmed.ncbi.nlm.nih.gov/38629555/] Teh WT, Stern C, Chander S, Hickey M. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res Int. 2014;2014:482968.  Johnson GGRJ, Park J, Helewa RM, Goldenberg BA, Nashed M, Hyun E. Total neoadjuvant therapy for rectal cancer: a guide for surgeons. Can J Surg. 2023 Apr 21;66(2):E196-E201. doi: 10.1503/cjs.005822. PMID: 37085291; PMCID: PMC10125160. [https://pubmed.ncbi.nlm.nih.gov/37085291/] Naren G, Guo J, Bai Q, Fan N, Nashun B. Reproductive and developmental toxicities of 5-fluorouracil in model organisms and humans. Expert Rev Mol Med. 2022 Jan 31;24:e9. doi: 10.1017/erm.2022.3. PMID: 35098910; PMCID: PMC9884763. [https://pubmed.ncbi.nlm.nih.gov/35098910/] National Comprehensive Cancer Network. (2026). NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (Version 2.2026). Retrieved from NCCN Guidelines for Rectal Cancer [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1449] Oktay, Kutluk M.D., Ph.D.. Expert Commentary on Fertility Preservation in Colorectal Cancers: Current State and Practical Tips for the Cancer Practitioner. Diseases of the Colon & Rectum 63(6):p 726-727, June 2020. | DOI: 10.1097/DCR.0000000000001688 [https://pubmed.ncbi.nlm.nih.gov/32479532/] Stal J, YI SY, Cohen-Cutler S, et al. Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates. Oncologist. 2022;27(7):579-586. doi:10.1093/oncolo/oyac052 [https://pubmed.ncbi.nlm.nih.gov/35708892/] Gentile G, Ciccarone M. Management of fertility preservation in young female patients with gastrointestinal cancer: A case series and systematic literature review. Curr Probl Cancer. 2025;57:101221. doi:10.1016/j.currproblcancer.2025.101221 [https://pubmed.ncbi.nlm.nih.gov/39598263/] Saif MW. Management of colorectal cancer in pregnancy: a multimodality approach. Clin Colorectal Cancer. 2005;5(4):247-256. doi:10.3816/ccc.2005.n.035 [https://pubmed.ncbi.nlm.nih.gov/16183863/] Rogers JE, Dasari A, Eng C. The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. Oncologist. 2016 May;21(5):563-70. doi: 10.1634/theoncologist.2015-0362. Epub 2016 Mar 21. PMID: 27000464; PMCID: PMC4861360. [https://pubmed.ncbi.nlm.nih.gov/27000464/] Jiang Q, Hua H. Fertility in young-onset colorectal patients with cancer: a review. Oncologist. 2024;29(10):e1237-e1245. doi:10.1093/oncolo/oyae141 [https://pubmed.ncbi.nlm.nih.gov/39292850/] Dolmans MM, Hollanders de Ouderaen S, Demylle D, Pirard C. Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment. J Assist Reprod Genet. 2015;32(8):1233-1237. doi:10.1007/s10815-015-0533-z [https://pubmed.ncbi.nlm.nih.gov/26162569/ Moawad NS, Santamaria E, Rhoton-Vlasak A, Lightsey JL. Laparoscopic Ovarian Transposition Before Pelvic Cancer Treatment: Ovarian Function and Fertility Preservation. J Minim Invasive Gynecol. 2017;24(1):28-35. doi:10.1016/j.jmig.2016.08.831 [https://pubmed.ncbi.nlm.nih.gov/27599763/] Fish R. Ovarian transposition in rectal cancer: uncertain benefit at a high price. Colorectal Dis. 2022;24(6):706-707. doi:10.1111/codi.16086 [https://pubmed.ncbi.nlm.nih.gov/35191146/] Ribeiro R, Baiocchi G, Moretti-Marques R, Linhares JC, Costa CN, Pareja R. Uterine transposition for fertility and ovarian function preservation after radiotherapy. Int J Gynecol Cancer. 2023;33(12):1837-1842. Published 2023 Dec 4. doi:10.1136/ijgc-2023-004723 [https://pubmed.ncbi.nlm.nih.gov/38104863/] Haggar F, Pereira G, Preen D, et al. Maternal and neonatal outcomes in pregnancies following colorectal cancer. Surg Endosc. 2013;27(7):2327-2336. doi:10.1007/s00464-012-2774-6 [https://pubmed.ncbi.nlm.nih.gov/23645367/] Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

You were told to try again. Maybe you were told it was bad luck, or to wait until it happened a third time before anyone would look. Here is what changed this year. In 2026, the American Society for Reproductive Medicine updated its definition of recurrent pregnancy loss for the first time since 2012. Two losses now meet the definition, not three, and a positive test that ended early counts. The old number kept women waiting for a third loss before the investigation even started. Here is the part no one tells you. Meeting the definition gets you a workup. It does not guarantee the workup is complete. After two or more losses, up to half of couples are told the same word. Unexplained. The losses are real. What gets called a complete workup is the question. This episode is the 9 specific things we most often find that are rarely checked before a woman is told her losses were unexplained or simply bad luck. Pull it up. Take notes. Bring it to your next appointment. The 9 patterns: Thyroid, the full panel and antibodies, not just TSH Antiphospholipid antibodies, tested correctly Chronic endometritis The reproductive microbiome, vaginal and seminal The gut, hidden gluten, and inflammation Sperm DNA fragmentation The male partner's full bloodwork Blood sugar and metabolic patterns The nervous system and progesterone These are the areas that sit outside a standard miscarriage workup. A 2012 meta-analysis in Human Reproduction, pooling sixteen studies and nearly three thousand couples, found miscarriage rates rose with sperm DNA damage, with about twice the relative risk. Unexplained rarely means there is nothing to find. It usually means the search stopped at the karyotype, one antiphospholipid test, the anatomy, and a TSH. For the full breakdown of every pattern, read the companion article, Recurrent Pregnancy Loss: The Functional Fertility Approach, at https://fabfertile.com/blogs/learn/recurrent-pregnancy-loss WHAT YOUR CLINIC MISSED The companion guide walks through all 9 of these patterns in more detail, so you can take it to your next appointment and ask the questions. Email hello@fabfertile.ca, subject line MISSED, and we will send you the guide. FUNCTIONAL FERTILITY SECOND OPINION A free 45-minute call where I review your labs, your history, your losses, and your partner's results with you. You leave knowing what your biology has been telling you and what your next decision could be. Email hello@fabfertile.ca, subject line FERTILE, or book here. ABOUT THE HOST I'm Sarah Clark, founder of Fab Fertile and host of Get Pregnant Naturally, a podcast with over one million downloads. My functional fertility team works with couples navigating low AMH and failed IVF, reviewing functional lab results, gut microbiome, food sensitivity, vaginal microbiome, nutrigenomics, HTMA, DUTCH, toxin testing, and bloodwork alongside nervous system work, to help identify patterns that may not have been considered. We work alongside your medical team, not instead of them. Sarah Clark, founder of Fab Fertile, host of Get Pregnant Naturally (1M+ downloads), and author of Fabulously Fertile. If this episode helped, leave a review on Apple Podcasts. It is how other women find this work. TIMESTAMPS 00:00 What "Unexplained" Means and What the 2026 Guideline Changed 01:30 Who's Reviewing Your Case at Fab Fertile 04:00 Thyroid: The Full Panel, Not Just TSH 05:50 Antiphospholipid Antibodies, Tested Correctly 06:30 Chronic Endometritis 07:30 The Reproductive Microbiome 08:30 The Gut, Hidden Gluten, and Inflammation 10:30 What Your Clinic Missed Guide 11:00 Sperm DNA Fragmentation 12:30 The Male Partner's Full Bloodwork 13:50 Blood Sugar and Metabolic Patterns 15:20 The Nervous System and Progesterone 16:30 What "Unexplained" Really Means 17:20 The Functional Fertility Second Opinion

A patient asked me this recently: "Dr. Shelley, I've heard that GLP-1 medications can cause muscle loss. Does that mean they can hurt my bones too?" It's an excellent question—and one we don't talk about nearly enough. In this episode, I'm walking you through what the research actually shows about GLP-1 medications and bone health, why weight loss itself poses a different risk to your skeleton, and the five non-negotiable steps you need to take to protect your bones while losing weight. This is the bone health conversation you need to hear before—or while—taking a GLP-1. Episode Highlights: What GLP-1 medications are and how they work in your body Does GLP-1 directly damage bones? What the research says The real issue: weight loss and how it affects bone health How your bones stay strong and why muscle matters Muscle loss during weight loss on GLP-1s (body composition breakdown) Who's at higher risk for weak bones and should be monitoring Eat enough protein: how much you actually need Strength training and resistance exercises for bone protection Getting enough calcium and vitamin D The DEXA bone density scan and when you should ask for one Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In a cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the impact of omidubicel-onlv (Omisirge) on patient outcomes, current research on reducing the risk of graft-vs-host disease (GVHD) among transplantation recipients, and strategies for providing effective prophylaxis during treatment, among other topics.

In a special edition of Oncology On the Go, Chinmay Jani, MD, joined CancerNetwork® in the studio to speak about different research initiatives he is involved with across precision oncology. He discussed ongoing work dedicated to validating and applying artificial intelligence (AI)–based tools in clinical work as well as overcoming immunotherapy resistance among patients with lung cancer.Jani, chief fellow in Hematology and Oncology at University of Miami Sylvester Comprehensive Cancer Center, first detailed findings from a study he presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting evaluating AI decision support in the context of EGFR-mutated non–small cell lung cancer (NSCLC). Although AI systems aligned with expert decision-making in frontline treatment, significant divergence was observed in second-line care, highlighting a need for more rigorous validation and clinical safeguards when integrating AI into oncologic decision-making. Improving documentation and using tools more ethically, Jani said, will also be critical for future applications of AI in field.Jani also spoke about the rapidly evolving thoracic oncology field based on research he and colleagues are leading at the University of Miami. Different investigations are exploring potential advancements in precision medicine, overcoming immunotherapy resistance, and early cancer detection to help elevate outcomes among patients with lung cancer. Looking ahead, Jani emphasized how novel therapeutics like tarlatamab-dlle (Imdelltra) and the incorporation of liquid biopsy may assist with the goal of turning lung cancer into “a chronic disease” where patients can survive not just for a few month or years but for decades.According to Jani, other key concerns in the field include the evolving landscape surrounding adolescent and young adult (AYA) patients, who may require different types of molecular testing and therapeutic needs compared with adult populations. Being able to detect more fusions and alterations that may inform therapeutic strategies via circulating tumor DNA plus circulating tumor RNA or through wider minimal residual disease testing, he said, represents another ongoing goal in terms of precision medicine.ReferenceJani C, Pérez-Granado J, Kalucha A, et al. Evaluating AI decision support in a rapidly evolving therapeutic landscape: EGFR-mutant metastatic NSCLC. J Clin Oncol. 2026;44(suppl 16):1630. doi:10.1200/JCO.2026.44.16_suppl.1630

During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. Hosted on Acast. See acast.com/privacy for more information.

353. A MAN BECOMES WHAT HE THINKS ABOUT MOST OF THE TIME --Ralph Waldo Emerson ROBERT A. YOHO, MD. President, American Society of Cosmetic Breast Surgery, 2012-2013. Fellow, American Society of Cosmetic Breast Surgery. Passed specialty boards of American Board of Dermatologic Cosmetic Surgery and the American Board of Laser Surgery. Fellow of American Academy of Cosmetic Surgery and American Society of Cosmetic Breast Surgery. California Academy of Cosmetic Surgery, past board member. BIoidentical Hormone Therapy, WorldLinkMedical. Emergency Medicine Board Certified and recertified. AUTHOR: A New Body in One Day. Published over 20 articles for physicians in medical journals. CLIMBER. 24 hour ascents of both El Capitan and Half Dome. Free ascents Astroman, Crucifix. First ascents Yosemite, Joshua Tree, Devils Tower. EAGLE SCOUT. TRIATHLON participant and age group winner. Founder & Director NEW BODY COSMETIC SURGERY ~ Accreditation Association Ambulatory Health Care (AAAHC) Certified & Accredited Surgical/Medical Practice & New Body Cosmetic Surgery DrYoho.com Support the show

353. A MAN BECOMES WHAT HE THINKS ABOUT MOST OF THE TIME --Ralph Waldo Emerson ROBERT A. YOHO, MD. President, American Society of Cosmetic Breast Surgery, 2012-2013. Fellow, American Society of Cosmetic Breast Surgery. Passed specialty boards of American Board of Dermatologic Cosmetic Surgery and the American Board of Laser Surgery. Fellow of American Academy of Cosmetic Surgery and American Society of Cosmetic Breast Surgery. California Academy of Cosmetic Surgery, past board member. BIoidentical Hormone Therapy, WorldLinkMedical. Emergency Medicine Board Certified and recertified. AUTHOR: A New Body in One Day. Published over 20 articles for physicians in medical journals. CLIMBER. 24 hour ascents of both El Capitan and Half Dome. Free ascents Astroman, Crucifix. First ascents Yosemite, Joshua Tree, Devils Tower. EAGLE SCOUT. TRIATHLON participant and age group winner. Founder & Director NEW BODY COSMETIC SURGERY ~ Accreditation Association Ambulatory Health Care (AAAHC) Certified & Accredited Surgical/Medical Practice & New Body Cosmetic Surgery DrYoho.com Support the show

"Geophysical tools for agricultural management: trends, challenges, and opportunities" with Dr. Sophia Becker Geophysical tools can help boost productivity and cut costs in the field, but, as with all areas of technology, work must be done to ensure smooth and useful implementation. In this episode, Sophia joins me to discuss her work studying opportunities and challenges for geophysical methods. If you would like more information about this topic, this episode's paper is available here: https://doi.org/10.1002/vzj2.70029 This paper is always freely available. Contact us at podcast@sciencesocieties.org or on Twitter @FieldLabEarth if you have comments, questions, or suggestions for show topics, and if you want more content like this don't forget to subscribe. If you'd like to see old episodes or sign up for our newsletter, you can do so here: https://fieldlabearth.libsyn.com/. If you would like to reach out to Sophia, you can find her here: sophbecker16@gmail.com Resources CEU Quiz: Coming soon Transcripts: https://www.rev.com/app/transcript/NmEzM2YwMTIyNTVkN2IyN2QwZjg0YjE1bzRzODNvLW4zQTRq/o/VEMxMDUwMTAxNTEy VZJ Agrogeophysics Special Section: https://acsess.onlinelibrary.wiley.com/toc/15391663/2021/20/4#heading-level-1-2 Geophysics conquering new territories: The rise of "agrogeophysics" by Sarah Garré: https://doi.org/10.1002/vzj2.20115 Field, Lab, Earth is Copyrighted by the American Society of Agronomy, Crop Science Society of America, and Soil Science Society of America.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve, with significant scientific advancements, regulatory updates, and strategic business moves shaping the landscape. Let's delve into these developments, starting with some key insights from oncology. In the realm of oncology, minimal residual disease (MRD) is becoming increasingly pivotal. Tumor-informed MRD is being leveraged to design more intelligent trials and interpret early responses, aiding in navigating developmental risks more effectively. This approach was a focal point of discussions at the American Society of Clinical Oncology's annual meeting, where experts emphasized the need to translate precision oncology discoveries into patient care, aiming to surmount existing challenges. The focus on MRD in oncology could lead to earlier detection of treatment responses and personalized therapeutic approaches. Verastem Oncology recently revisited its strategy concerning its combination treatment of avutometinib plus defactinib for metastatic pancreatic cancer. While clinical trials produced moderate results, the company is now redirecting focus toward other promising candidates in its pipeline. Similarly, Novocure faced setbacks as its tumor-treating electric fields device did not achieve its primary endpoint in a Phase 3 glioblastoma trial. These outcomes highlight the persistent challenges in tackling aggressive brain cancers. On the regulatory front, Spero Therapeutics achieved a significant milestone with FDA approval for Utebzi to treat complicated urinary tract infections. This approval marks a turnaround from a previous rejection four years ago, facilitated through a partnership with GSK. Meanwhile, in Europe, Cinnagen secured approval for Zandoriah, a biosimilar of teriparatide, to treat osteoporosis in adults—a testament to their investment in infrastructure and manufacturing capabilities. The industry also sees growing interest in cell therapy automation, with companies like Cellares and Ori Biotech leading the charge. These advancements reflect an industry-wide push towards more efficient manufacturing processes for cell therapies. In metabolic health, Novo Nordisk's oral GLP-1 drug Wegovy has gained significant traction due to its brand familiarity among healthcare providers, crucial in its competition with Eli Lilly's Foundayo. Market trends reveal competitive dynamics within obesity treatments as Novo Nordisk's oral Wegovy outpaces Eli Lilly's offerings due to strong brand recognition. Biogen's acquisition of Raythera for $1 billion underscores its strategic intent to enhance its portfolio with promising preclinical immunology assets. Such acquisitions highlight broader industry strategies focusing on expanding pipelines through targeted investments. This move aligns with Biogen's focus on autoimmune diseases and enhances its preclinical portfolio. In business development news, LabGenius Therapeutics partnered with LG Chem to utilize AI and machine learning for designing multispecific antibodies targeting tumors. This collaboration highlights the growing importance of artificial intelligence in accelerating drug discovery processes within oncology. Clinical trials continue to yield promising results. F2G and Shionogi's antifungal small molecule olorofim demonstrated efficacy comparable to Ambisome in treating invasive aspergillosis—an advancement crucial for infectious diseases with limited treatment options. D&D Pharmatech's Zabopegdutide showed an impressive improvement rate in fibrosis during Phase 2 trials for metabolic dysfunction-associated steatohepatitis, emphasizing the potential of protein-based therapies in treating metabolic liver disorders. Corporate launches reflect strategic maneuvers aimed at advancing therapeutic developments. Innoviva introduced Nortiva Bio to focus on long-acting oral medicines using acquired platform technology from Lyndra Therapeutics—aiming to revolutionize women's health through sustained-release formulations. The financial landscape also shows active movement, exemplified by Kardigan's $400 million IPO aimed at progressing cardiovascular drugs into advanced trials. Alvotech's public offering signals a commitment to biosimilar medicines—a sector poised for growth due to rising demand for cost-effective biologic therapies. Overall, these developments reflect a robust innovation pipeline within the pharmaceutical and biotech industries as they strategically address complex diseases through novel therapies and technologies. As scientific progress accelerates alongside strategic corporate actions, these changes promise enhanced patient care outcomes through groundbreaking treatments that cater to unmet medical needs worldwide.Support the show

Sarah Little, senior vice president-business development for the American Society of Travel Advisors (ASTA), talks with James Shillinglaw of Insider Travel Report at last month's ASTA Travel Advisor Conference in San Diego about how ASTA's growing collection of conferences and events is helping support travel advisors in a variety of ways. From the Travel Advisor Conference to the ASTA River Cruise Expo to several other signature events, ASTA has created a series of highly successful meetings and conferences that can help advisors build their business through training and education. For more information, visit www.asta.org.  All our Insider Travel Report video interviews are archived and available on our Youtube channel  (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox. 

In this episode of the DermSurgery Digest, you'll hear quick, high-yield summaries with practical takeaways on the cosmetic and general dermatology articles featured in the June 2026 issue of Dermatologic Surgery. Featured contributors this month are Isabela Jones, MD, and George Hruza, MD, MBA.This podcast is hosted by Naomi Lawrence, MD, Digital Content Editor for Dermatologic Surgery, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery.The remaining cosmetic and general dermatology articles from the June issue are highlighted in-depth in a companion episode, Spotlight, published on June 12, 2026.We welcome your feedback. Please contact communicationstaff@asds.net.

In this episode of the DermSurgery Digest, you'll hear quick, high-yield summaries with practical takeaways on the surgical oncology and reconstruction articles featured in the June 2026 issue of Dermatologic Surgery. Featured contributors this month are Tara Jennings, MD, and Bradley Merritt, MD.This podcast is hosted by Naomi Lawrence, MD, Digital Content Editor for Dermatologic Surgery, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery.The remaining surgical oncology and reconstruction articles from the June issue are highlighted in-depth in a companion episode, Spotlight, published on June 12, 2026.We welcome your feedback. Please contact communicationstaff@asds.net.

Jessica Klement, vice president of advocacy for the American Society of Travel Advisors (ASTA), talks with James Shillinglaw of Insider Travel Report at last month's ASTA Travel Advisor Conference in San Diego about how ASTA is actively and effectively lobbying federal and state government on behalf of travel advisors. Find out all the ways that ASTA is working for you to make sure government regulations, laws and legislation won't harm your business. For more information, visit www.asta.org. All our Insider Travel Report video interviews are archived and available on our Youtube channel  (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox. 

From Season 2 – Do you have generational biases at work? Dr. Carrie Spell-Hansson shares how you can start challenging assumptions and having more meaningful conversations with colleagues across generations. Recorded at EA Ignite Fall 2023 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

Peter Lobasso, vice president and general counsel for the American Society of Travel Advisors (ASTA), talks with James Shillinglaw of Insider Travel Report at last month's ASTA Travel Advisor Conference in San Diego about ASTA's Verified Travel Advisor (VTA) program, what it includes, how many have passed it and what it means to be a VTA. Lobasso also discusses other ASTA initiatives such as its efforts to support cruise lines that have eliminated non-commissionable fares (NCFs). For more information, visit www.asta.org.  All our Insider Travel Report video interviews are archived and available on our Youtube channel  (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox. 

Twenty-two steps to reach an airway is not a quirky workflow problem, it's a patient safety problem. We're turning our attention to a neuro-interventional radiology (Neuro IR) suite where cables, monitors, and a poorly positioned anesthesia machine created a cramped, high-friction non-operating room anesthesia (NORA) environment. Joined by John Edwards, CRNA, we unpack how a real-world quality improvement project at the University of Kentucky Medical Center turned staff frustration into an evidence-based anesthesia workspace redesign.We start with what triggered the change: frontline clinicians describing barriers to optimal patient care, unsafe ergonomics, and a layout that made simple tasks unnecessarily hard. From there, we connect the dots to broader NORA safety expectations, including the American Society of Anesthesiologists guidance on having sufficient space, equipment access, and the ability to reach the patient quickly. Them, the team brings anesthesia staff, interventional radiology personnel, and facilities managers together to redesign the room with minimal disruption.You'll hear the practical interventions that made the difference, like cable management using existing ceiling infrastructure, switching to a more compact anesthesia machine, and repositioning equipment to restore clear access to the patient. The results are striking: smoother movement, less clutter, improved morale, and a dramatic reduction in the distance to the airway. If you work in any NORA location, this is a blueprint for safer anesthesia workflows.Subscribe for more NORA safety and patient safety insights, share this with a colleague who works off-site, and leave a review to help more clinicians find the show.For show notes & transcript, visit our episode page at apsf.org: https://www.apsf.org/podcast/311-from-cable-chaos-to-one-step-airway-access/© 2026, The Anesthesia Patient Safety Foundation

The Fellow of the American Society for Health Care Risk Management (FASHRM) designation recognizes those with outstanding achievements and contributions to the field of health care risk management. Come listen to Sharon Rateike, recent FASHRM recipient, discuss her risk journey and how she went about receiving the FASHRM designation in January 2026.

The Fellow of the American Society for Health Care Risk Management (FASHRM) designation recognizes those with outstanding achievements and contributions to the field of health care risk management. Come listen to Deena Berry, recent FASHRM recipient, discuss her risk journey and how she went about receiving the FASHRM designation in January 2026.

Dr. Ashok K. Shetty is a University Distinguished Professor in the Department of Cell Biology and Genetics and Associate Director of the Institute for Regenerative Medicine at Texas A&M University, Naresh Vashisht College of Medicine. He is developing treatments for neurological and neurodegenerative disorders using stem cells and stem cell-derived products, such as extracellular vesicles. These are tiny vesicles secreted by stem cells that carry microRNAs and proteins. Once they make their way into the brain, they can induce beneficial changes in neural cells to improve brain function. Science takes up a lot of Ash's time, but when he's able to get a moment to himself, he enjoys spending time with family, cycling on a stationary bicycle, playing brain games like Sudoku, and going out to see movies at the theater. Ash earned his Ph.D. in Neuroscience from the All India Institute of Medical Sciences in New Delhi, and he completed postdoctoral research at Montana State University and Duke University. Afterward, he joined the faculty at Duke University in the Division of Neurosurgery. He joined the faculty at Texas A&M University College of Medicine in 2011. In 2024, he was honored with the University Distinguished Professor Award from Texas A&M University, and he has also received the College of Medicine's Senior Research Excellence Award. In addition, Ash is a Fellow of the American Association for the Advancement of Science and the American Society for Neural Transplantation and Repair. He has received the Research Career Scientist Award from the United States Department of Veterans Affairs, has been recognized among the "World's Top 1% of Scientists" across all scientific fields, and he was the 2025 honoree of Fast Company's World Changing Ideas. In this interview, Ash shares details about his life and his work in science.

Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning. In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available. Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now! Episode Highlights: Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors Participants lost an average of 28.3% of their body weight in 80 weeks Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight Nearly everyone with prediabetes reversed it and returned to normal blood sugar Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity The highest discontinuation rate due to side effects was only 11%—mainly GI issues Retatrutide is not yet FDA approved but anticipated to launch early 2027 Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

The Distinguished Fellow of the American Society for Health Care Risk Management (DFASHRM) designation recognizes those with superior achievements and contributions to the healthcare risk profession. Come listen to Myka Whitman, recent DFASHRM recipient, discuss her risk journey and how she went about receiving the DFASHRM designation in January 2026.

Mark Meader, executive vice president-corporate of the American Society of Travel Advisors (ASTA), talks with James Shillinglaw of Insider Travel Report at last month's ASTA Travel Advisor Conference in San Diego about ASTA's priorities over the past year and in the future. Meader also talks about why ASTA's has also focused on corporate travel and corporate agencies. For more information, visit www.asta.org. All our Insider Travel Report video interviews are archived and available on our Youtube channel (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox.

In this episode of the DermSurgery Digest, you'll hear in-depth summaries and expert commentary on select cosmetic and general dermatology articles featured in the June 2026 issue of Dermatologic Surgery. Featured contributors Isabela Jones, MD, and George Hruza, MD, MBA, share key insights and perspectives on the articles: Photographic Assessment of Cosmetic Outcome in Postsurgical Facial Scars Favors Rapidly Absorbable Polyglactin 910 Over Fast Absorbing Gut: A Blinded Randomized Clinical TrialRegenerative Aesthetics: Present Advances and Emerging Strategies for Optimized Tissue HealthDoes Prior Treatment With Facial Injectables Increase the Risk of Rhytidectomy Complications?Safety and Efficacy of a Multi-use Neurotoxin Protocol in Academic SettingsThis podcast is hosted by Naomi Lawrence, MD, Digital Content Editor for Dermatologic Surgery, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery.The remaining cosmetic and general dermatology articles from the June issue are highlighted in a companion episode, Rapid Pearls, publishing on June 19, 2026.We welcome your feedback. Please contact communicationstaff@asds.net.

In this episode of the DermSurgery Digest, you'll hear in-depth summaries and expert commentary on select surgical oncology and reconstruction articles featured in the June 2026 issue of Dermatologic Surgery. Featured contributors Tara Jennings, MD, and Bradley Merritt, MD, share key insights and perspectives on the articles: Updates for Management of Merkel Cell Carcinoma of the Head and Neck: A Systematic ReviewThe CLASS Project: A Proof-of-Concept Machine Learning-Driven Complexity Level Algorithm for Surgical Scheduling in Mohs Micrographic SurgeryPharmacologic Methods to Reduce Postoperative Bleeding During the First Stage of the Interpolated Forehead Flap Repair: A Systematic ReviewThis podcast is hosted by Naomi Lawrence, MD, Digital Content Editor for Dermatologic Surgery, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery.The remaining surgical oncology and reconstruction articles from the June issue are highlighted in a companion episode, Rapid Pearls, publishing on June 19, 2026.We welcome your feedback. Please contact communicationstaff@asds.net.

Sixty thousand people a year get a procedure that could change their pain forever...and most have never heard of it.In this episode of Real Things Living, Brigitte Cutshall sits down with Dr. Steven Falowski, a neurosurgeon with nearly 20 years of experience who is helping lead the charge against chronic pain — without opioids. Dr. Falowski breaks down how spinal cord stimulation has evolved from bulky external battery packs to quarter-sized implants that quietly re-train your nervous system to stop feeling pain. From spine injuries and arthritis to migraines and post-surgical recovery, this conversation opens the door to a world of solutions most patients don't even know exist.3 Takeaways:(1) Pain is more common than heart disease, cancer, and diabetes combined — yet the tools to treat it effectively remain largely unknown to the public.(2) Spinal cord stimulators don't just block pain anymore — they re-register nerves to stop perceiving pain altogether.(3) New research is putting stimulators in at the time of spine surgery to prevent chronic pain before it even starts. If you or a loved one is silently navigating chronic pain, look beyond the pill bottle and research local pain specialists who utilize modern spinal cord stimulation. Explore trusted resources through the American Society of Pain and Neuroscience (ASPN) at https://aspnpain.com/Learn more about Dr. Falowski's practice at https://www.asclancaster.com/physicians/steven-m-falowski-md/

Lee Thomas, chair of the American Society of Travel Advisors (ASTA) talks with James Shillinglaw of Insider Travel Report at this month's ASTA Travel Advisor Conference about what ASTA's successes over the past year. Thomas, founder of NousTravel, also tells us why he got involved with ASTA and what he hopes the group will accomplish in in the next year, his second as ASTA chair. For more information, visit www.asta.org.  All our Insider Travel Report video interviews are archived and available on our Youtube channel  (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox. 

Dr. Andrew Fox, organizational culture expert, author, and Anglican priest, discusses the growing influence of groupthink in American society, the importance of independent thinking, and why he believes the pursuit of applause is replacing the pursuit of truth. https://drandrewfox.com/

The FiltrateJoel Topf kidneyboy.bsky.socialSpecial GuestsDr. Samir Parikh, President of the American Society of NephrologyProf. Donal Reddan, President, Irish Nephrology SocietyProf. Catherine GodsonEditing Joel TopfThe Kidney Connection written and performed by Timothy YauShow Notes Tubular SecretionsJoel Topf, the Dublin Port Greenway LinkCatherine Godson: never heard of the Dublin Port GreenwaySamir Parikh: Trinity College Dublin and specifically the Eavan Boland Library, named after the Irish poet. Donal Reddan: Something about rugby

Looking for a real community of executive assistants and business operations professionals that's free to join, supportive, and meets you where you are? ASAP Circle community manager Deanna Danger shares how she has benefited from the ASAP network and how you can, too. Recorded at EA Ignite Fall 2025 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

Step behind the curtains of the post-anesthesia care unit (PACU) in this compelling episode of the Legal Nurse Podcast. Host Pat Iyer sits down with Paul Sayeg, a seasoned registered nurse, legal nurse consultant, and expert witness, to explore the hidden world of PACU nursing, a fast-paced, detail-intensive environment where patients emerge from anesthesia at their most vulnerable. With over two decades of clinical experience, Paul shares his insights on patient monitoring, the critical role of the Aldrete and modified Aldrete scores, and the unique challenges facing nurses in this high-stakes setting. Together, they dig into the standardized tools and clinical judgment required for safe patient recovery in various settings, from hospitals to same-day surgery centers. Real-world cases and stories illustrate the life-and-death importance of nurse vigilance, thorough documentation, and seamless teamwork. The discussion also peels back the layers of system-level pressures such as "factory line healthcare," that can contribute to liability risks and medical errors. Listeners will gain a valuable perspective on how a healthy PACU culture supports early intervention and patient safety, and how expert witnesses piece together complex cases using standards published by the American Society of Peri Anesthesia Nurses (ASPAN). Whether you're a legal nurse consultant, healthcare professional, or simply curious about what happens after surgery, this episode delivers a candid look at the science, systems, and human factors behind successful post-anesthesia care. What You'll Learn in This Episode on Behind the Curtain: PACU Nursing, Complications, and Legal Risks  Here are 5 discussion questions answered in the podcast: What are the different settings in which post-anesthesia care is delivered, and how do patient acuity and procedure type influence these settings? How does the Aldrete score assist nurses in post-anesthesia care, and what are its key assessment areas? In what ways can documentation errors, such as missing vital signs, impact the accuracy of the Aldrete score and patient safety? What is the significance of the modified Aldrete score, and how has it evolved to better reflect current anesthesia practices? How do standards of care published by organizations like ASPAN influence clinical practice and legal nurse consulting? Get the free transcripts and also learn about other ways to subscribe. Go to Legal Nurse Podcasts subscribe options by using this short link: http://LNC.tips/subscribepodcast. https://youtu.be/RRAvj91rV-c Your Presenter for Behind the Curtain: PACU Nursing, Complications, and Legal Risks  Pat Iyer Pat Iyer is a seasoned legal nurse consultant and business coach, renowned for her expertise in guiding new legal nurse consultants to successfully break into the field. As the host of the Legal Nurse Podcast, Pat addresses critical challenges that legal nurse consultants face, such as difficulty in landing clients and a lack of response from attorneys. Through her insightful episodes, she emphasizes the importance of effectively communicating one's value to potential clients. With a wealth of experience, Pat has empowered countless consultants to overcome these hurdles and thrive in their careers. Connect with Pat Iyer by email at patiyer@legalnusebusiness.com Paul Sayegh Three nouns: I'm a nurse, traveler, and baker.Background: Paul Sayegh is a Registered Nurse with over two decades of Clinical experience, primarily in pre-operative care and the PACU at an academic medical center in San Francisco. He brings a perioperative perspective to his work as a legal nurse consultant and expert witness, with a focus on communication, transitions of care, and patient safety. When he's not on this podcast, Paul is caring for patients in pre-op and PACU, traveling whenever he can, and spending time in the kitchen baking for friends, family, and colleagues. Connect with Paul Sayegh by email at paulsayeghrnbsn@gmail.com

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations.

A 25-year-old pregnant woman presents with a 1-day history of progressive pain and swelling. The foot is cold, pulseless and neurologic function is deteriorating by the hour. Imaging shows a massive iliofemoral DVT. Now both the limb and the pregnancy are threatened. Do you anticoagulate, thrombolyse or operate? Join us as we break down the management and decision making behind this rare but devastating case.Hosts:·      Christian Hadeed -PGY 4 General Surgery, Brookdale Hospital Medical Center·      Paul Haser -Division Chief, Vascular Surgery, Brookdale Hospital Medical Center·      Andrew Harrington, Vascular surgery, Brookdale Hospital Medical Center·      Lucio Flores, Vascular surgery, Brookdale Hospital Medical CenterLearning objectives:-       Recognize the clinical presentation and pathophysiology of phlegmasia cerulea dolens-       Describe how pregnancy affects decision making in patients with phlegmasia and venous thromboembolic disease-       Discuss the goals of treatment for patients with DVT's and identify when operative intervention is indicated-       Describe the sequelae of DVT's and how this relates to post thrombotic syndrome-       Review the indications, risks, and limitations of anticoagulation, catheter-directed thrombolysis, thrombectomy, and fasciotomy in the management of DVT and phlegmasia.-       Explain the role of IVUS in managing venous thromboembolic disease and May Thurner syndromeReferences:-       Vedantham, S., Goldhaber, S. Z., Julian, J. A., Kahn, S. R., Jaff, M. R., Cohen, D. J., Magnuson, E., Razavi, M. K., Comerota, A. J., Gornik, H. L., Murphy, T. P., Lewis, L., Duncan, J. R., Nieters, P., Derfler, M. C., Filion, M., Gu, C.-S., Kee, S., Schneider, J., … Kearon, C. (2017). Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. New England Journal of Medicine, 377(23), 2240–2252. https://doi.org/10.1056/NEJMoa1615066-       Gomes, M. S., Guimarães, M., & Montenegro, N. (2019). Thrombolysis in pregnancy: A literature review. Journal of Maternal-Fetal & Neonatal Medicine, 32(14), 2418–2428. https://doi.org/10.1080/14767058.2018.1438402-       Mangla, A., & Hamad, H. (2023). May-Thurner syndrome. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554377/-       Bates, S. M., Rajasekhar, A., Middeldorp, S., McLintock, C., Rodger, M. A., James, A. H., et al. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: Venous thromboembolism in the context of pregnancy. Blood Advances, 2(22), 3317–3359. https://doi.org/10.1182/bloodadvances.2018024802-       Kahn, S. R., Comerota, A. J., Cushman, M., Evans, N. S., Ginsberg, J. S., Goldenberg, N. A., et al. (2014). The postthrombotic syndrome: Evidence-based prevention, diagnosis, and treatment strategies. Circulation, 130(18), 1636–1661. https://doi.org/10.1161/CIR.0000000000000130 https://pubmed.ncbi.nlm.nih.gov/25246013/Sponsor URL: https://www.goremedical.com/If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

My interview with Steven begins at 28 minutes Watch and Subscribe to 6 Questions with Steven Beschloss Read and Subscribe to Steven Beschloss Writer, journalist, editor, filmmaker, professor For more than four decades, Steven Beschloss has created award-winning stories, as a writer, journalist, editor and filmmaker. Consistent in this work is a passion for writing and a belief in the transformative power of story. As a writer and journalist -- from the U.S. and Europe -- his writing on international and urban affairs, politics, economics, education, art and culture has been published by The New Yorker,  The Washington Post, The New York Times, The New Republic, Smithsonian, The Chicago Tribune, The Wall Street Journal, Parade Magazine, National Geographic, The Economist Intelligence Unit and dozens of other print and online outlets. He's been nominated for a Pulitzer Prize, selected Journalist of the Year in Virginia, and honored with a magazine writing award by the American Society of Journalists and Authors. He is the author of the narrative book, The Gunman and His Mother: Lee Harvey Oswald, Marguerite Oswald and The Making of an Assassin, a bestselling Amazon Kindle Single and newly updated and published by Open Road Media. He is also the co-author of Adrift: Charting Our Course Back to a Great Nation (Prometheus Books), a featured guest on MSNBC, Fox Business and NPR, and he writes and publishes America, America, a popular Substack newsletter focused on politics and society, democracy and justice. Beschloss is also an adjunct professor at New York University's Arthur L. Carter Journalism Institute. He was previously a professor of practice at Arizona State University, where he founded and directed the Narrative Storytelling Initiative and worked at the College of Global Futures and the Walter Cronkite School of Journalism and Mass Communication. At ASU, he also led narrative development, serving under the president's office. In addition to his work as a journalist, writing and editing for magazines and newspapers, Beschloss has taken on various roles as a scriptwriter, producer and director for film and television. His projects have included documentary and fiction films for European television, such as The Miracle, shot in Saint Petersburg, Russia, for the French-German ARTE channel and first screened at the Pompidou Centre in Paris. In 2003, he co-wrote and co-produced Paris, a noir thriller shot in Los Angeles and Las Vegas that premiered in competition at the Tribeca Film Festival, was acquired by 20th Century Fox Home Entertainment, sold to more than 20 countries, and aired for nearly two years on the Showtime movie channels. A Chicago native and married father of two daughters, Beschloss has lived and worked in New York, London, Helsinki, Moscow and Los Angeles.  He is a graduate of Haverford College, earned his master's degree at Northwestern University's Medill School of Journalis On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete Listen rate and review on Apple Podcasts Listen rate and review on Spotify Pete On Instagram Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on Twitter Pete Personal FB page Stand Up with Pete FB page Gift a Subscription https://www.patreon.com/PeteDominick/gift Send Pete $ Directly on Venmo All things Jon Carroll  Buy Ava's Art  Subscribe to Piano Tuner Paul Paul Wesley on Substack Listen to Barry and Abigail Hummel Podcast Listen to Matty C Podcast and Substack Follow and Support Pete Coe Hire DJ Monzyk to build your website or help you with Marketing

Join us in this episode as we explore the evolving field of cardiovascular medicine with Michael S. Sacks, Professor and Director of the James T. Willerson Center for Cardiovascular Modeling and Simulation at the University of Texas at Austin. As a leading expert in cardiovascular modeling, Professor Sacks focuses on developing patient-specific, simulation-based technologies that improve our understanding of heart and heart valve disease. What's his goal? To advance treatment strategies by helping physicians better predict outcomes and design therapies tailored to individual patients… Click play to learn about: The two major problems with valve therapy. How computational modeling is transforming the diagnosis and treatment of heart disease. Why patient-specific simulations may improve surgical planning and clinical outcomes. The limitations of current valve replacement technologies. Professor Sacks has held numerous leadership roles throughout his distinguished career, including serving as Technical Editor of the Journal of Biomechanical Engineering. He is an inaugural Fellow of the Biomedical Engineering Society, a Fellow of the American Society of Mechanical Engineers, and a Fellow of the American Institute for Medical and Biological Engineering. His honors include the Van C. Mow Medal from the ASME Bioengineering Division, the University of Pittsburgh Chancellor's Distinguished Research Award, the Richard Skalak Distinguished Lectureship from Columbia University, and the SKT Lectureship from the City College of New York. In 2006, he was recognized as one of Scientific American's 50 Leaders in Science and Technology. Connect with Professor Sacks:  LinkedIn University of Texas Profile  Google Scholar Profile Willerson Center for Cardiovascular Modeling and Simulation Oden Institute for Computational Engineering & Sciences

Can I restart my GLP-1? The answer is yes — but it requires a strategic plan.  In this episode I'm walking you through exactly what happens to your body when you restart a GLP-1, why the timing of your break matters more than you think, how to restart safely without landing yourself in misery, the biggest mistakes I see patients make, and how to get back on track without shame or guilt. Restarting doesn't have to mean starting completely over. But how you restart matters. Listen now!   Episode Highlights: Why restarting at your previous dose will make you seriously sick What happens to your hunger, cravings, and fullness signals when you restart How long you've been off determines your restart dose The critical question that changes everything: weeks vs. months off Why weight regain after stopping is biology, not failure 3 practical strategies to minimize side effects and rebuild tolerance How to stay mentally on track without shame or comparison   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

PAN lanza carta disparatada después del evento de la American Society con Salinas Pliego: JacarandaEnlace para apoyar vía Patreon:https://www.patreon.com/julioastilleroEnlace para hacer donaciones vía PayPal:https://www.paypal.me/julioastilleroCuenta para hacer transferencias a cuenta BBVA a nombre de Julio Hernández López: 1539408017CLABE: 012 320 01539408017 2Tienda:https://julioastillerotienda.com/ Hosted on Acast. See acast.com/privacy for more information.

Dr. Eric Winer a past President of the American Society of Clinical Oncology speaks with current ASCO President Dr. Elizabeth Mittendorf about the developments revealed at this annual worldwide conference. Yale Cancer Center Visit: https://medicine.yale.edu/cancer/ Email: canceranswers@yale.edu Call 203-785-4095

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations.Braunstein is an associate professor in the Department of Medicine and course co-director of the Hematology/Oncology System at NYU Grossman Long Island School of Medicine, as well as the fellowship program director of Hematology/Oncology at NYU Langone Health. Zahid is a first-year fellow at NYU Grossman Long Island School of Medicine.The discussion focused on the following abstracts:·      Abstract 7512o   Combining belantamab mafodotin-blmf (Blenrep) with daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone produced rapid activity among patients with transplant-ineligible newly diagnosed multiple myeloma in the phase 1/2 BelaDRd study (EUCT-2024-515634-32).o   The progression-free survival (PFS) benefits observed in the trial support further evaluation of the quadruplet in a phase 3 study compared with other novel combination regimens in NDMM.·      Abstract 6505o   Revumenib (Revuforj) maintenance therapy after allogeneic stem cell transplantation showed feasibility in a heavily pretreated cohort of patients with acute myeloid leukemia (AML).o   Outcomes appeared favorable vs historical cohorts, supporting prospective assessment of maintenance menin inhibition among those with AML.·      Abstract 1503o   In a retrospective analysis of electronic medical records for 293 patients who received CAR T-cell therapy for lymphoma (n = 175), multiple myeloma (n = 106), or B-cell acute lymphoblastic leukemia (n = 12), outpatient monitoring was associated with significantly fewer hospital days without increased emergency department visits or 30-day mortality.o   These findings show the potential for lower healthcare utilization for patients who receive CAR T-cell therapy in the outpatient setting.·      Abstract LBA7000o   Adding tafasitamab (Monjuvi) and lenalidomide to rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) significantly improved PFS vs R-CHOP alone among those with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in the phase 3 frontMIND trial (NCT04824092).o   The data may support tafasitamab plus lenalidomide and R-CHOP as a potential new standard of care in the frontline treatment of patients with cell-of-origin subtypes of high-risk DLBCL.References Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: phase 1/2 BelaDRd study. J Clin Oncol. 2026;44(suppl 16):7512. doi:10.1200/JCO.2026.44.16_suppl.7512 Goulart H, Okeleji O, DiNardo CD, et al. Revumenib as maintenance for AML following allogeneic stem cell transplantation. J Clin Oncol. 2026;44(suppl 16):6505. doi:10.1200/JCO.2026.44.16_suppl.6505 Bowen SG, Abdallah N, Pritchett JC, et al. Impact of outpatient CAR T-cell therapy administration on healthcare utilization in patients with hematologic malignancies. J Clin Oncol. 2026;44(suppl 16):1503. doi:10.1200/JCO.2026.44.16_suppl.1503 Lenz, G, Trněný M, Burke JM, et al. frontMIND: phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2026;44(suppl 17):LBA7000. doi:10.1200/JCO.2026.44.17_suppl.LBA7000

This week, we return to a lively conversation with Dr. Soong-Chan Rah, hosted by Octavio and Claire back in 2020. Here, they consider the need for the North American church to break free from Western cultural captivity and embrace the diversity of our communities in our gathered worship and theology. Soong-Chan emphasizes the importance of diversity, community, and authentic cultural expression in faith communities. If this conversation piques your interest, consider joining him in the classroom this summer. He will be teaching "Cultural Intelligence for a Changing Church" from July 6-10. Soong-Chan's BioSoong-Chan Rah is the Robert Boyd Munger Professor of Evangelism and Church Renewal at Fuller Theological Seminary. He holds a ThD from Duke Divinity School, with a primary field of study in theology and ethics, and a secondary field of study in American evangelical history. He also holds an MDiv and a DMin, with a concentration in urban ministry leadership, from Gordon-Conwell Theological Seminary, as well as a ThM from Harvard University, with a thesis on the immigrant church.Dr. Rah has authored or co-authored over a half-dozen books, which have won many awards. These include The Next Evangelicalism: Freeing the Church from Western Cultural Captivity(IVP, 2009); Many Colors: Cultural Intelligence for a Changing Church (Moody, 2010); Prophetic Lament: A Call for Justice in Troubled Times (IVP, 2015); Return to Justice: Six Movements that Reignited Our Contemporary Evangelical Conscience (with Gary Vanderpol; Brazos, 2016); Unsettling Truths: The Ongoing, Dehumanizing Legacy of the Doctrine of Discovery (with Mark Charles; IVP, 2019); and Forgive Us: Confessions of a Compromised Faith (with Mae Elise Cannon, Lisa Sharon Harper, and Troy Jackson; Zondervan, 2014).Dr. Rah is an ordained pastor in the Evangelical Covenant Church and a member of the Academy for Evangelism in Theological Education, the American Academy of Religion, and the American Society of Missiology. He speaks on the topics of the witness of the church, cross-cultural ministry, and social justice at a wide range of academic conferences, seminaries, Christian colleges, local churches, denominational gatherings, and ministry conferences across the United States and around the world.Regent College PodcastThanks for listening. Please like, rate and review us on your podcast platform of choice and share this episode with a friend. Follow Us on Social MediaFacebookInstagramYoutubeKeep in TouchRegent CollegeSummer ProgramsRegent College Newsletter

Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s annual meeting for a weekend of buzzy data drops, practice-changing posters and insightful sessions. In this week’s episode of "The Top Line," Fierce Biotech and Fierce Pharma’s Darren Incorvaia, Zoey Becker and Angus Liu break down the biggest takeaways from their weekend of reporting live from the Windy City. From “nutty” in vivo CAR-T data to a historic first for a Chinese biotech asset, ASCO 2026 reflected new and continuing trends within the evolving state of cancer care today. To learn more about the topics in this episode: ASCO: Revolution Medicines confident in RAS leadership as rivals square up ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary See omnystudio.com/listener for privacy information.

Have you used "the steeple" in meetings with executives? Learn what this means and so much more from body language expert Janine Driver. Recorded at EA Ignite Fall 2025 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

Sybil Derrible, professor of urban engineering at the University of Illinois, Chicago, and author of the popular science title ‘The Infrastructure Book: How Cities Work and Power Our Lives,' joins the program to discuss the state of global infrastructure. He is also a fellow of the American Society of Civil Engineers, and was a lead author on the United Nations Environmental Program Seventh Global Environment Outlook (GEO-7). Derrible invites your questions and comments. He can be reached at derrible@uic.edu. (06/2026)

Sybil Derrible, professor of urban engineering at the University of Illinois, Chicago, and author of the popular science title ‘The Infrastructure Book: How Cities Work and Power Our Lives,' joins the program to discuss the state of global infrastructure. He is also a fellow of the American Society of Civil Engineers, and was a lead author on the United Nations Environmental Program Seventh Global Environment Outlook (GEO-7). Derrible invites your questions and comments. He can be reached at derrible@uic.edu. (06/2026)

Sybil Derrible, professor of urban engineering at the University of Illinois, Chicago, and author of the popular science title ‘The Infrastructure Book: How Cities Work and Power Our Lives,' joins the program to discuss the state of global infrastructure. He is also a fellow of the American Society of Civil Engineers, and was a lead author on the United Nations Environmental Program Seventh Global Environment Outlook (GEO-7). Derrible invites your questions and comments. He can be reached at derrible@uic.edu. (06/2026)

Eleonora Teplinsky, MD, is the head of breast and gynecologic medical oncology and Valley-Mount Sinai Comprehensive Cancer Center in Paramus, New Jersey, as well as an ASCO breast cancer expert. She explained the most compelling research results on breast cancer presented at the 2026 American Society of Clinical Oncology Annual Meeting. Listen to the episode to hear Dr. Teplinsky explain: the importance of the OPTIMA study, as well as her caveats about the results the latest results from the ASCENT-04 study what progression-free survival 2 (PFS2) is and how it helps doctors decide which treatments should be given first what we do and don't know about GLP-1 medicines and cancer

At the 2026 American Society of Clinical Oncology Annual Meeting poster session, we asked four scientists to discuss their research. Listen to the episode to hear: Peter Stanfield, of the University of Wisconsin, explains his research on cancer screening rates in transgender and gender-diverse people. Nico Gotera, of the University of Texas Health Science Center, explains research on GLP-1 medicines and rates of breast cancer in postmenopausal women. Anna Tanasijevic, of the Dana-Farber Cancer Institute, explains research on how much cancer survivors exercise. Xianghui Zou, of NYU Langone Health, explains research on the timing of immunotherapy infusions for people with early-stage triple-negative breast cancer.

You stopped your GLP-1 and now you're wondering can I just restart where I left off? Why am I so hungry again? Why are the side effects back? Did the medication stop working? These are questions I hear all the time in my practice. And the answer is not as simple as picking back up where you stopped. In this episode I am walking you through exactly what happens biologically when you stop a GLP-1, why restarting feels different than when you first started, how to restart safely, the common mistakes I see patients make, and how to get back on track mentally without shame. A pause does not erase your progress. But how you restart matters more than you think. Listen now! Episode Highlights: Why stopping your medication is not failure and why your biology is not your weakness What actually happens to your hunger, cravings, and fullness signals when you go off GLP-1s Why restarting at your old dose can land you in the emergency room How long is too long to be off and what dose to restart at based on your break The 3 most common restart mistakes  Practical tips to minimize side effects and rebuild tolerance the right way How to stay mentally on track without shame or comparison to your first journey Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

FCC Chairman Brendan Carr joins after Disney filed early license renewal applications for its broadcast stations at the agency's request. Then, Erin Brockovich discusses the environmental concerns around the data center buildout and a new map she created to help track them. Plus, we take a look at what to expect from the American Society of Clinical Oncology's annual meeting, which kicks off today. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CardioNerds Dr. Joseph Kassab, Dr. Mariana Garcia-Arango, and Dr. Christopher Mason explore the technological revolution of Coronary CT Angiography (CCTA) with expert faculty Dr. Michael Gallagher. The discussion details how CCTA has evolved into a frontline diagnostic and preventive tool, moving beyond simple anatomy to incorporate physiology via CT-FFR and biology through AI-driven plaque quantification. The episode reviews landmark evidence like the SCOT-HEART and PROMISE trials, the nuances of CAD-RADS 2.0 reporting, and the emerging role of AI in monitoring treatment response and personalizing cardiovascular care. Critically, they also discuss some of the assumptions and limitations of these techniques. Stay tuned for a matching review article to be submitted to US Cardiology Review, the official Journal of CardioNerds. This episode was supported by an independent medical education grant from HeartFlow. All CardioNerds education is planned, produced, and reviewed solely by CardioNerds.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Multimodality Cardiovascular Imaging PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll Pearls Shift in Paradigm: CCTA is no longer just an anatomic test; with some key limitations, it can provide anatomy, physiology (CT-FFR), and plaque biology (AI-CPA) in a single non-invasive scan. The “Power of Zero” vs. Plaque: While a normal CCTA has a >95% negative predictive value, future MIs often arise from non-obstructive plaque that traditional stress tests might miss. CAD-RADS 2.0 Utility: The addition of plaque burden modifiers (P1–P4) is a “game changer,” allowing clinicians to identify high-risk patients who need aggressive lipid-lowering despite having only mild stenosis. CT-FFR as a Virtual Stress Test: CT-FFR uses computational fluid dynamics to simulate blood flow, potentially reducing unnecessary invasive catheterizations by approximately 61% without sacrificing safety. Seeing the Invisible: AI-based quantitative plaque analysis (QCPA) can identify “subvisual” plaque and low-attenuation (lipid-rich) components that are the primary drivers of acute coronary syndromes. Show Notes How has the role of CCTA changed compared to traditional functional testing? Historically, stress testing answered “is there ischemia today?”, which often reflects late-stage disease. CCTA identifies disease across the entire spectrum, asking “is there atherosclerosis and how much plaque is present?”. Landmark evidence: SCOT-HEART showed a 41% relative risk reduction in MI at 5 years attributed to intensified preventive therapies, and PROMISE showed CCTA was better at selecting patients who truly needed invasive angiography. Diagnostic CCTA imaging depends on the protocol, contrast timing, heart rate, heart rhythm, breathholding, scanner quality, and several patient factors (obesity, prior stents, heavy calcification, complex bypass anatomy, and motion artifact all may limit imaging). “CCTA is exceptional for the right patient, with the right scanner, and the right team.” What are the key modifiers introduced in CAD-RADS 2.0, and why do they matter? CAD-RADS 2.0 moved beyond stenosis severity to include plaque burden (P0 to P4), high-risk plaque (HRP) features, and the presence of ischemia based on CT-FFR. It serves as a clinical decision support tool: a patient with mild (25-49%) stenosis but “extensive” (P4) plaque burden is considered high risk and warrants aggressive risk factor modification. How is CT-FFR calculated, and when is it most useful in clinical practice? CT-FFR uses resting CCTA data and computational fluid dynamics to create a 3D model of coronary flow during simulated maximal hyperemia. It is often used for intermediate lesions (40–90% stenosis) to predict if they are  ischemia-producing, guiding the decision whether to proceed with invasive angiography.  The assumptions necessary for this computational modeling may not apply well to patients with microvascular dysfunction, significant myocardial scar or prior infarction, or ventricular hypertrophy. Still, data indicate that CT-FFR performs similarly to PET in predicting hemodynamically significant lesions.  CT-FFR performs well at the extremes (either clearly normal or clearly abnormal). Accuracy dips, however, in the intermediate range (~0.75-0.80), where decision-making is most critical. In this grey zone, additional factors can help guide the approach, including the amount of myocardium supplied, translesional gradient, and plaque features.   CT-FFR has not been validated in distal segments, stented segments, heavily calcified coronary arteries, or in patients with severe aortic stenosis. Caution with CT-FFR should be utilized in very calcified coronary segments.  What is AI-based quantitative plaque analysis (QCPA), and what metrics are ready for clinical use? This is potentially a paradigm shift, moving away from stenosis-centric thinking to a more disease burden and plaque biology focus. QCPA uses deep learning algorithms to automatically segment the vessel wall and quantify plaque volume in mm³. Ready for “prime time” metrics include: Total Plaque Volume (TPV), non-calcified plaque volume, and Low-Attenuation Plaque (LAP) burden. Can serial CCTA be used to monitor the effectiveness of medical therapies like statins? While not yet a routine guideline-driven practice, trials like PARADIGM and EVAPORATE show that therapies can stabilize plaque; notably, CCTA is better for monitoring than CAC scores, which can be misleading as statins often increase plaque calcification as part of the stabilization process. There are no randomized trials that serial CCTAs improve outcomes. Cost and radiation exposure will be notable limitations. Serial scan timing, scan acquisition and interpretation standardization would be key. Dr. Gallagher notes that we are moving toward a world in which plaque burden may become a “treatment biomarker,” similar to tumor burden in oncology.  References 1. Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies: JACC State-of-the-Art Review. Abdelrahman KM, Chen MY, Dey AK, et al. Journal of the American College of Cardiology. 2020;76(10):1226-1243. doi:10.1016/j.jacc.2020.06.076. 2. Non-Invasive Imaging in Coronary Syndromes: Recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in Collaboration With the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Edvardsen T, Asch FM, Davidson B, et al. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2022;35(4):329-354. doi:10.1016/j.echo.2021.12.012. 3. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021;78(22):e187-e285. doi:10.1016/j.jacc.2021.07.053. 4. Contemporary, Non-Invasive Imaging Diagnosis of Chronic Coronary Artery Disease. van der Bijl P, Gulati M, Saraste A, et al. Lancet (London, England). 2025;406(10519):2577-2587. doi:10.1016/S0140-6736(25)01586-7. 5. State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart Association. Slipczuk L, Blankstein R, Bucciarelli-Ducci C, et al. Circulation. 2025;152(23):e443-e466. doi:10.1161/CIR.0000000000001394. 6. Diagnostic Performance of Fractional Flow Reserve Derived From Coronary CT Angiography: The ACCURATE-CT Study. Li C, Hu Y, Jiang J, et al. JACC. Cardiovascular Interventions. 2024;17(17):1980-1992. doi:10.1016/j.jcin.2024.06.027. 7. Clinical Outcomes Based on Coronary Computed Tomography-Derived Fractional Flow Reserve and Plaque Characterization. Sato Y, Motoyama S, Miyajima K, et al. JACC. Cardiovascular Imaging. 2024;17(3):284-297. doi:10.1016/j.jcmg.2023.07.013. 8. Clinical Use of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve: Expert Consensus by an International Working Group. Tang CX, Leipsic JA, Nørgaard BL, et al. European Radiology. 2026;:10.1007/s00330-025-12313-6. doi:10.1007/s00330-025-12313-6. 9. Diagnostic accuracy of computed tomography–derived fractional flow reserve: a systematic review. Cook CM, Petraco R, Shun-Shin MJ, et al. JAMA Cardiol. 2017;2(7):803-810. Doi:10.1001/jamacardio.2017.1314 10. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). Nørgaard BL, Leipsic J, Gaur S, et al. J Am Coll Cardiol. 2014;63(12):1145-1155. Doi:10.1016/j.jacc.2013.11.043 11. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. Driessen RS, Danad I, Stuijfzand WJ, et al. J Am Coll Cardiol. 2019;73(2):161-173. Doi:10.1016/j.jacc.2018.10.056. 12. 1-year outcomes of FFRCT-guided care in patients with suspected coronary disease: the PLATFORM study. Douglas PS, De Bruyne B, Pontone G, et al. J Am Coll Cardiol. 2016;68(5):435-445. Doi:10.1016/j.jacc.2016.05.057. 13. Comparison of an initial risk-based testing strategy vs usual testing in stable symptomatic patients with suspected coronary artery disease: the PRECISE randomized clinical trial. Douglas PS, Nanna MG, Kelsey MD, et al; PRECISE Investigators. JAMA Cardiol. 2023;8(10):904-914. Doi:10.1001/jamacardio.2023.2595. 14. Diagnostic and clinical value of FFRCT in stable chest pain patients with extensive coronary calcification: the FACC study. Mickley H, Veien KT, Gerke O, et al. JACC Cardiovasc Imaging. 2022;15(6):1046-1058. doi:10.1016/j.jcmg.2021.12.010. 15. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Williams MC, Kwiecinski J, Doris M, et al. Circulation. 2020;141(18):1452-1462. doi:10.1161/CIRCULATIONAHA.119.044720. 16. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD. Nurmohamed NS, Bom MJ, Jukema RA, et al. JACC. Cardiovascular Imaging. 2024;17(3):269-280. doi:10.1016/j.jcmg.2023.05.020. 17. Interaction of AI-Enabled Quantitative Coronary Plaque Volumes on Coronary CT Angiography, FFRCT, and Clinical Outcomes: A Retrospective Analysis of the ADVANCE Registry. Dundas J, Leipsic J, Fairbairn T, et al. Circulation. Cardiovascular Imaging. 2024;17(3):e016143. doi:10.1161/CIRCIMAGING.123.016143. 18. Prognostic Value of AI-Based Quantitative Coronary CTA vs Human Reader-Based Visual Assessment: Results From the CONFIRM2 Registry. van Rosendael A, Nakanishi R, Bax JJ, et al. JACC. Cardiovascular Imaging. 2026;19(3):345-359. doi:10.1016/j.jcmg.2025.09.021.13. Pericoronary Adipose Tissue as a Marker of Cardiovascular Risk: JACC Review Topic of the Week. Tan N, Dey D, Marwick TH, Nerlekar N. Journal of the American College of Cardiology. 2023;81(9):913-923. doi:10.1016/j.jacc.2022.12.021. 19. Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: Final Results of the EVAPORATE Trial. Budoff MJ, Bhatt DL, Kinninger A, et al. European Heart Journal. 2020;41(40):3925-3932. doi:10.1093/eurheartj/ehaa652. 20. Coronary CT Angiography Evaluation With Artificial Intelligence for Individualized Medical Treatment of Atherosclerosis: A Consensus Statement From the QCI Study Group. Schulze K, Stantien AM, Williams MC, et al. Nature Reviews. Cardiology. 2026;23(2):100-115. doi:10.1038/s41569-025-01191-6.